PRESS RELEASE

Q4 2025 — Press release

Q4 2025PDF · 17 pages906 KB
E A R N I N G S R E L E A S E
ELEVANCE HEALTH REPORTS FOURTH QUARTER AND
FULL YEAR 2025 RESULTS; SETS FULL YEAR 2026 OUTLOOK
• 4Q 2025 operating revenue of $49.3 billion; FY 2025 of $197.6 billion
• 4Q 2025 diluted EPS1 of $2.47; adjusted diluted EPS2 of $3.33
• FY 2025 diluted EPS1 of $25.21; adjusted diluted EPS2 of $30.29
• Projected FY 2026 GAAP diluted EPS1 to be at least $22.30
• Projected FY 2026 adjusted diluted EPS2 to be at least $25.50
• Returned $4.1 billion of capital to shareholders in 2025
• Reaffirming long-term earnings algorithm; recalibrating segment margin targets
Indianapolis, IN - January 28, 2026 - Elevance Health, Inc. (NYSE: ELV) reported fourth
quarter and full year 2025 results.
"Elevance Health delivered fourth quarter results in line with our outlook, reflecting disciplined
execution in a dynamic environment. As we enter 2026, our focus is on advancing affordability
and making healthcare easier to access and navigate for the members we serve. Through
pricing discipline and targeted investments, we are strengthening the earnings power of our
diversified platform and remain confident in our ability to return to at least 12% adjusted EPS
growth in 2027."
Gail K. Boudreaux
President and Chief Executive Officer
1. Earnings per diluted share ("EPS").
2. Refer to GAAP reconciliation tables on pages 13 and 14 herein for reconciliation of GAAP to adjusted measures.
1

-- 1 of 17 --

Elevance Health
Consolidated Enterprise Highlights
(Unaudited)
(In billions) Three Months Ended Twelve Months Ended
December 31,
2025 December 31,
2024 December 31,
2025 December 31,
2024
Operating Revenue1 $49.3 $45.0 $197.6 $175.2
Operating Gain1,2 $0.3 $0.7 $7.2 $7.9
Adjusted Operating Gain1,3 $0.4 $0.8 $7.5 $9.3
Operating Margin1 0.6% 1.5% 3.6% 4.5%
Adjusted Operating Margin1,3 0.8% 1.9% 3.8% 5.3%
1. See “Basis of Presentation” on page 5 herein.
2. Operating Gain for the three and twelve months ended December 31, 2025, and December 31, 2024, includes items that are excluded from
adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.
3. Adjusted Operating Gain for the three and twelve months ended December 31, 2025, and December 31, 2024, excludes items that are excluded
from adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.
Operating revenue was $49.3 billion in the fourth quarter of 2025, an increase of $4.3 billion, or 10
percent compared to the prior year quarter. Operating revenue was $197.6 billion in 2025, an increase of
$22.4 billion, or 13 percent. The increase in revenue for the quarter and year was driven by higher
premium yields in our Health Benefits segment, contributions from acquisitions, and growth in Medicare
Advantage membership, partially offset by membership attrition in our Medicaid business.
The benefit expense ratio was 93.5 percent in the fourth quarter, an increase of 110 basis points
compared to the prior year period, reflecting higher medical cost trend primarily in our Affordable Care
Act health plans and heightened Medicare Part D seasonality driven by Inflation Reduction Act changes.
For the year, our benefit expense ratio was 90.0 percent, an increase of 150 basis points year over year,
driven by elevated medical cost trends.
Days in Claims Payable was 41.3 days as of December 31, 2025, a decrease of 0.1 days from
September 30, 2025, and a decrease of 1.9 days compared to December 31, 2024.
The operating expense ratio was 11.0 percent in the fourth quarter and 10.6 percent for the full year. On
an adjusted basis, the corresponding operating expense ratios were 10.8 percent and 10.5 percent. We
maintained expense discipline while investing to support and strengthen our workforce, scale Carelon's
capabilities, and accelerate technology adoption across the enterprise.
Cash Flow & Balance Sheet
Operating cash flow was $4.3 billion in 2025, approximately 0.8 times GAAP net income. As of
December 31, 2025, cash and investments at the parent company totaled approximately $2.6 billion.
During the fourth quarter of 2025, the Company repurchased 1.4 million shares of its common stock for
$471 million, at a weighted average price of $335.64, and paid a quarterly dividend of $1.71 per share,
representing a distribution of cash totaling $377 million. As of December 31, 2025, the Company had
approximately $6.7 billion of Board approved share repurchase authorization remaining.
2

-- 2 of 17 --

Health Benefits is comprised of Individual, Employer Group risk-based, Employer Group fee-based,
BlueCard®, Medicare, Medicaid, and Federal Employee Program businesses.
Health Benefits
Reportable Segment Highlights
(Unaudited)
(In billions) Three Months Ended Twelve Months Ended
December 31,
2025 December 31,
2024 December 31,
2025 December 31,
2024
Operating Revenue1 $41.8 $37.6 $167.1 $150.3
Operating Gain1,2 ($0.2) $0.2 $4.2 $6.2
Adjusted Operating Gain1,3 ($0.2) $0.2 $4.2 $6.3
Operating Margin1 (0.5%) 0.6% 2.5% 4.2%
Adjusted Operating Margin1 (0.5%) 0.6% 2.5% 4.2%
1. See “Basis of Presentation” on page 5 herein.
2. Operating Gain for the three and twelve months ended December 31, 2024 includes items that are excluded from adjusted shareholders' net
income. See "GAAP Reconciliation" on pages 13 and 14 herein.
3. Adjusted Operating Gain for three and twelve months ended December 31, 2024 excludes $16 and $66 million, respectively, of 2024 business
dispositions and related items adjusted out of adjusted shareholders' net income for the Health Benefits segment.
Health Benefits segment operating revenue was $41.8 billion in the fourth quarter of 2025, an increase
of $4.3 billion, or 11 percent compared to the fourth quarter of 2024. Operating revenue was $167.1
billion in 2025, an increase of $16.8 billion, or 11 percent. The increases for the quarter and year were
driven primarily by higher premium yields, contributions from acquisitions, and growth in our Medicare
Advantage membership, partially offset by membership attrition in our Medicaid business.
The Company reported an adjusted operating loss of $0.2 billion in the fourth quarter of 2025 and an
adjusted operating gain of $4.2 billion for the full year. Adjusted operating results in both periods were
impacted primarily by higher medical cost trend.
Medical membership totaled approximately 45.2 million as of December 31, 2025, a decrease of 0.5
million, or 1 percent, year over year, driven by attrition in our Medicaid business.
3

-- 3 of 17 --

Carelon is comprised of CarelonRx and Carelon Services.
Carelon
Reportable Segment Highlights
(Unaudited)
(In billions) Three Months Ended Twelve Months Ended
December 31,
2025 December 31,
2024 December 31,
2025 December 31,
2024
Operating Revenue1,2 $18.7 $14.7 $71.7 $53.9
Operating Gain1,3 $0.6 $0.6 $3.4 $2.9
Adjusted Operating Gain1,4,5 $0.6 $0.6 $3.4 $3.1
Operating Margin1 3.1% 3.9% 4.7% 5.4%
Adjusted Operating Margin1 3.3% 4.4% 4.8% 5.8%
1. See “Basis of Presentation” on page 5 herein.
2. Operating revenue for the three and twelve months ended December 31, 2024 includes $0.2 and $0.8 billion, respectively, of revenue related to
2024 business dispositions and related items that have been excluded from adjusted operating gain.
3. Operating Gain for the three and twelve months ended December 31, 2025, and December 31, 2024, includes items that are excluded from
adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.
4. Adjusted Operating Gain for three and twelve months ended December 31, 2025 excludes $38 million of 2025 business dispositions and related
items adjusted out of adjusted shareholders' net income for the Carelon segment.
5. Adjusted Operating Gain for the three and twelve months ended December 31, 2024 excludes $74 and $215 million, respectively, of 2024
business dispositions and related items adjusted out of adjusted shareholders' net income for the Carelon segment.
Operating revenue for Carelon was $18.7 billion in the fourth quarter of 2025, an increase of $3.9
billion, or 27 percent compared to the prior year period, driven by growth in CarelonRx product revenue,
the expansion of Carelon Services risk-based solutions, and the acquisition of CareBridge. Operating
revenue was $71.7 billion in 2025, an increase of $17.8 billion, or 33 percent.
Adjusted operating gain for Carelon totaled $0.6 billion in the fourth quarter, approximately flat year
over year. On a full year basis, adjusted operating gain was $3.4 billion in 2025, an increase of $0.3
billion, or 10 percent, driven by improved CarelonRx performance and growth in Carelon Services risk-
based solutions.
4

-- 4 of 17 --

Quarterly Dividend
On January 27, 2026, the Audit Committee of the Company's Board of Directors declared a first quarter
2026 dividend to shareholders of $1.72 per share. The first quarter dividend is payable on March 25,
2026 to shareholders of record at the close of business on March 10, 2026.
About Elevance Health
Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity.
The company supports consumers, families, and communities across the entire healthcare journey –
connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s
companies serve approximately 104 million consumers through a diverse portfolio of industry-leading
medical, pharmacy, behavioral, clinical, home health, and complex care solutions. For more information,
please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on
LinkedIn.
Conference Call and Webcast
Management will host a conference call and webcast today at 8:30 a.m. Eastern Standard Time (“EST”)
to discuss the company’s fourth quarter and full year 2025 results and 2026 outlook. The conference call
should be accessed at least 15 minutes prior to the start of the call with the following numbers:
888-947-9963 (Domestic) 888-566-0046 (Domestic Replay)
312-470-0178 (International) 203-369-3677 (International Replay)
The access code for today's conference call is 3972058. There is no access code for the replay. The
replay will be available from 11:30 a.m. EST today, until the end of the day on February 27, 2026. The
call will also be available through a live webcast at www.elevancehealth.com under the “Investors” link.
A webcast replay will be available following the call.
Basis of Presentation
1. Operating revenue and operating gain/loss are the key measures used by management to evaluate
performance in each of its reporting segments, allocate resources, set incentive compensation
targets and to forecast future operating performance. Operating gain/loss is calculated as total
operating revenue less benefit expense, cost of products sold and operating expense. It does not
include net investment income, net gains/losses on financial instruments, interest expense,
amortization of other intangible assets, gains/losses on extinguishment of debt or income taxes, as
these items are managed in a corporate shared service environment and are not the responsibility of
operating segment management. Refer to pages 13 and 14 for the GAAP reconciliation tables.
2. Operating margin is defined as operating gain divided by operating revenue.
Elevance Health Contacts:
Investor Relations Media
Nathan Rich Leslie Porras
Investor.Relations@elevancehealth.com Leslie.Porras@elevancehealth.com
5

-- 5 of 17 --

Elevance Health
Earnings Release Financial Schedules and Supplementary Information
Quarter & Year Ended December 31, 2025
• Membership and Other Metrics
• Quarterly & Full Year Consolidated Statements of Income
• Condensed Consolidated Balance Sheet
• Condensed Consolidated Statement of Cash Flows
• Supplemental Financial Information - Reportable Segments
• Supplemental Financial Information - Reconciliation of Medical Claims Payable
• Reconciliation of Non-GAAP Financial Measures
• Financial Guidance Summary
• Membership Guidance Summary
6

-- 6 of 17 --

Elevance Health
Membership and Other Metrics
(Unaudited)
Change from
Medical Membership (in thousands) December 31,
2025 December 31,
2024 September 30,
2025 December 31,
2024 September 30,
2025
Individual . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,307 1,287 1,354 1.6% (3.5%)
Employer Group Risk-Based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,617 3,713 3,616 (2.6%) —%
Commercial Risk-Based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,924 5,000 4,970 (1.5%) (0.9%)
BlueCard® . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,509 6,630 6,394 (1.8%) 1.8%
Employer Group Fee-Based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20,583 20,569 20,608 0.1% (0.1%)
Commercial Fee-Based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27,092 27,199 27,002 (0.4%) 0.3%
Medicare Advantage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,230 2,066 2,245 7.9% (0.7%)
Medicare Supplement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 882 891 877 (1.0%) 0.6%
Total Medicare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,112 2,957 3,122 5.2% (0.3%)
Medicaid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8,500 8,917 8,645 (4.7%) (1.7%)
Federal Employee Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,604 1,661 1,630 (3.4%) (1.6%)
Total Medical Membership . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45,232 45,734 45,369 (1.1%) (0.3%)
Other Metrics (in millions)
CarelonRx Quarterly Adjusted Scripts . . . . . . . . . . . . . . . . . . . . . . . . . . . 88.5 82.9 85.0 6.8% 4.1%
Carelon Services Consumers Served . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91.8 101.1 97.6 (9.2%) (5.9%)
7

-- 7 of 17 --

Elevance Health
Consolidated Statements of Income
(Unaudited)
(In millions, except per share data)
Three Months Ended
December 31
Twelve Months Ended
December 31
2025 2024 Change 2025 2024 Change
Revenues
Premiums . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 40,690 $ 36,245 12.3% $ 164,639 $ 144,166 14.2%
Product revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,460 6,714 (3.8%) 24,470 22,630 8.1%
Service fees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,161 2,030 6.5% 8,475 8,408 0.8%
Total operating revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49,311 44,989 9.6% 197,584 175,204 12.8%
Net investment income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 493 527 (6.5%) 2,194 2,051 7.0%
Net losses on financial instruments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (57) (74) NM (653) (445) NM
Gain on sale of business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — — NM — 201 NM
Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49,747 45,442 9.5% 199,125 177,011 12.5%
Expenses
Benefit expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38,065 33,500 13.6% 148,223 127,567 16.2%
Cost of products sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,522 6,012 (8.2%) 21,178 19,750 7.2%
Operating expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,415 4,804 12.7% 20,984 20,025 4.8%
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 366 340 7.6% 1,402 1,185 18.3%
Amortization of other intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164 180 (8.9%) 628 580 8.3%
Total expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49,532 44,836 10.5% 192,415 169,107 13.8%
Income before income tax expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215 606 (64.5%) 6,710 7,904 (15.1%)
Income tax expense (benefit) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (331) 193 NM 1,049 1,933 (45.7%)
Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 546 413 32.2% 5,661 5,971 (5.2%)
Net loss attributable to noncontrolling interests . . . . . . . . . . . . . . . . . . . . . 1 5 NM 1 9 NM
Shareholders' net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 547 $ 418 30.9% $ 5,662 $ 5,980 (5.3%)
Shareholders' earnings per diluted share . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 2.47 $ 1.81 36.5% $ 25.21 $ 25.68 (1.8%)
Diluted shares . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221.8 231.1 (4.0%) 224.6 232.9 (3.6%)
Benefit expense as a percentage of premiums . . . . . . . . . . . . . . . . . . . . . . . . . 93.5% 92.4% 110 bp 90.0% 88.5% 150 bp
Operating expense as a percentage of total operating revenue . . . . . . . . . . . . . 11.0% 10.7% 30 bp 10.6% 11.4% (80) bp
Income before income tax expense as a percentage of total revenue . . . . . . . . 0.4% 1.3% (90) bp 3.4% 4.5% (110) bp
"NM" = calculation not meaningful
8

-- 8 of 17 --

Elevance Health
Condensed Consolidated Balance Sheet
(In millions)
December 31,
2025 December 31,
2024
Assets (Unaudited)
Current assets:
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $9,491 $8,288
Fixed maturity and equity securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26,624 26,393
Premium and other receivables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21,542 19,071
Other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,344 4,700
Assets held for sale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — 490
Total current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63,001 58,942
Long-term investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11,960 10,784
Property and equipment, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,679 4,652
Goodwill and other intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39,544 40,371
Other noncurrent assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,310 2,140
Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $121,494 $116,889
Liabilities and equity
Liabilities
Current liabilities:
Medical claims payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $17,084 $15,746
Short-term borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150 365
Current portion of long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,099 1,649
Other current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22,702 22,668
Liabilities held for sale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — 153
Total current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41,035 40,581
Long-term debt, less current portion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30,797 29,218
Other noncurrent liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,636 5,664
Total liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77,468 75,463
Total shareholders’ equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43,882 41,315
Noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144 111
Total equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44,026 41,426
Total liabilities and equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $121,494 $116,889
9

-- 9 of 17 --

Elevance Health
Condensed Consolidated Statement of Cash Flows
(Unaudited)
(In millions)
Twelve Months Ended
December 31
2025 2024
Operating activities
Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 5,661 $ 5,971
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,546 1,393
Share-based compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276 191
Changes in operating assets and liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (3,680) (1,719)
Other non-cash items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 487 (28)
Net cash provided by operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,290 5,808
Investing activities
Proceeds from sale of investments, net of maturities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69 586
Net purchases of subsidiaries, net of cash acquired/sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88 (4,446)
Purchases of property and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (1,116) (1,256)
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (385) (51)
Net cash used in investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (1,344) (5,167)
Financing activities
Net change in short-term and long-term borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 629 6,200
Repurchase and retirement of common stock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (2,605) (2,900)
Cash dividends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (1,529) (1,508)
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,767 (599)
Net cash provided by (used in) financing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (1,738) 1,193
Effect of foreign exchange rates on cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (5) (6)
Change in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,203 1,828
Cash and cash equivalents at beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8,288 6,526
Cash and equivalents included in assets held for sale at end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — (66)
Cash and cash equivalents at end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $9,491 $8,288
10

-- 10 of 17 --

REPORTABLE SEGMENTS
Elevance Health has four reportable segments: Health Benefits (comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal
Employee Program businesses); CarelonRx; Carelon Services; and Corporate & Other (comprised of businesses that do not individually meet the quantitative thresholds for an operating division as
well as corporate expenses not allocated to our other reportable segments).
Elevance Health
Reportable Segment Details
(Unaudited)
(In millions) Three Months Ended December 31 Twelve Months Ended December 31
2025 2024 Change 2025 2024 Change
Operating Revenue
Health Benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $41,835 $37,580 11.3% $167,094 $150,275 11.2%
CarelonRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11,644 9,977 16.7% 43,400 35,961 20.7%
Carelon Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7,015 4,769 47.1% 28,316 17,961 57.7%
Corporate & Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (83) (14) NM6 463 309 49.8%
Eliminations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (11,100) (7,323) NM6 (41,689) (29,302) NM6
Total Operating Revenue1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $49,311 $44,989 9.6% $197,584 $175,204 12.8 %
Operating Gain (Loss)
Health Benefits2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ($220) $207 NM6 $4,158 $6,243 (33.4%)
CarelonRx3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 724 533 35.8% 2,418 2,172 11.3%
Carelon Services2,3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (150) 35 NM6 960 717 33.9%
Corporate & Other2,3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (45) (102) NM6 (337) (1,270) NM6
Total Operating Gain1,4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $309 $673 (54.1%) $7,199 $7,862 (8.4%)
Operating Margin
Health Benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (0.5%) 0.6% (110) bp 2.5% 4.2% (170) bp
CarelonRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6.2% 5.3% 90 bp 5.6% 6.0% (40) bp
Carelon Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (2.1%) 0.7% (280) bp 3.4% 4.0% (60) bp
Total Operating Margin1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.6% 1.5% (90) bp 3.6% 4.5% (90) bp
Health Benefits Revenue Details
(In millions) Three Months Ended December 31 Twelve Months Ended December 31
2025 2024 Change 2025 2024 Change
Health Benefits Operating Revenue
Commercial . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $12,747 $11,851 7.6% $50,401 $46,816 7.7%
Individual5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,248 2,117 6.2% 9,295 8,295 12.1%
Medicare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10,762 9,054 18.9% 44,752 36,795 21.6%
Medicaid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14,500 12,755 13.7% 56,620 51,937 9.0%
Federal Employee Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,826 3,920 (2.4%) 15,321 14,727 4.0%
Total Health Benefits Operating Revenue1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $41,835 $37,580 11.3% $167,094 $150,275 11.2%
1. See “Basis of Presentation” on page 5 herein.
2. Operating Gain for the three and twelve months ended December 31, 2024 included $90 and $281 million, respectively, of 2024 business dispositions and related items; including $74 and $215 million, respectively, for the Carelon Services segment; and $16 and $66 million,
respectively, for the Health Benefits segment. Operating Gain for the three and twelve months ended December 31, 2024 included $66 and $224 million, respectively, of transaction and integration related costs, $12 and $692 million, respectively, of litigation and settlement expenses,
and $0 and $268 million, respectively, of business optimization charges, all of which reside in the Corporate & Other reportable segment.
3. Operating Gain for the three and twelve months ended December 31, 2025 included $41 million of 2025 business dispositions and related items; including $45 million for the CarelonRx segment; ($7) million for the Carelon Services segment; and $3 million for the Corporate & Other
segment. Operating Gain for the three and twelve months ended December 31, 2025 included $54 and $236 million, respectively, of transaction and integration related costs, $5 and $24 million, respectively, of litigation and settlement expenses, and ($34) and ($38) million,
respectively, of business optimization charges, all of which reside in the Corporate & Other reportable segment.
4. Operating Gain for the three and twelve months ended December 31, 2025, and December 31, 2024, included items excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.
5. The Individual business, including ACA products, is reported as part of Commercial Operating Revenue.
6. "NM" = calculation not meaningful.
11

-- 11 of 17 --

Elevance Health
Reconciliation of Medical Claims Payable
Years Ended December 31
2025 2024 2023
(In millions) (Unaudited)
Gross medical claims payable, beginning of year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 15,580 $ 15,865 $ 15,348
Ceded medical claims payable, beginning of year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (13) (7) (6)
Net medical claims payable, beginning of year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15,567 15,858 15,342
Business combinations and purchase adjustments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 344 143 —
Net incurred medical claims:
Current year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145,566 125,370 121,798
Prior years redundancies1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (1,290) (1,731) (1,571)
Total net incurred medical claims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144,276 123,639 120,227
Net payments attributable to:
Current year medical claims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130,265 110,930 107,146
Prior years medical claims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13,141 13,143 12,565
Total net payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143,406 124,073 119,711
Net medical claims payable, end of year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16,781 15,567 15,858
Ceded medical claims payable, end of year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48 13 7
Gross medical claims payable, end of year2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 16,829 $ 15,580 $ 15,865
Current year medical claims paid as a percentage
of current year net incurred medical claims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89.5 % 88.5% 88.0%
Prior year redundancies in the current year as a percentage of prior year
net medical claims payable less prior year redundancies in the current year . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.0 % 12.3% 11.4%
Prior year redundancies in the current year as a
percentage of prior year net incurred medical claims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.0 % 1.4% 1.4%
1. Negative amounts reported for net incurred medical claims related to prior years result from claims being settled for amounts less than originally estimated.
2. Excludes insurance lines other than short duration.
12

-- 12 of 17 --

Elevance Health
GAAP Reconciliation
(Unaudited)
This document references non-GAAP measures, including “Adjusted Shareholders’ Net Income,” “Adjusted Shareholders’ Net Income Per Share,” “Adjusted EPS,” “Adjusted Operating Gain,” “Adjusted Operating Expense”
and “Adjusted Operating Expense Ratio,” which are non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and are not intended to
be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP are available below. In
addition to these non-GAAP measures, references are made to the measures “Operating Revenue” and “Operating Gain/Loss,” “Operating Margin” and “Adjusted EPS”. Operating revenue and operating gain/loss are the key
measures used by management to evaluate performance in each of its reportable segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated
as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other
intangible assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Each of
these measures is provided to further aid investors in understanding and analyzing Elevance Health’s operating and financial results. A reconciliation of Operating Revenue to Total Revenue is set forth in the Consolidated
Statements of Income herein. A reconciliation of the non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP, together with a reconciliation of reportable segments operating gain
to income before income tax expense, is provided below. Prior amounts may be grouped differently to conform to the current presentation. Net adjustment items per share may not sum due to rounding. A reconciliation of
Operating Revenue to Total Revenue is set forth in the Consolidated Statements of Income herein.
Three Months Ended
December 31 Twelve Months Ended
December 31
(In millions, except per share data) 2025 2024 Change 2025 2024 Change
Shareholders' net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 547 $ 418 30.9% $ 5,662 $ 5,980 (5.3%)
Add / (Subtract):
Amortization of other intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164 180 628 580
Net losses on financial instruments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57 74 653 445
Transaction and integration related costs1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 66 236 224
Business dispositions and related items2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 90 41 281
Litigation and settlement expenses1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 12 24 692
Gain on sale of business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — — — (201)
Business optimization charges1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (34) — (38) 268
Tax impact of non-GAAP adjustments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (95) (93) (402) (575)
Net adjustment items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192 329 1,142 1,714
Adjusted shareholders' net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 739 $ 747 (1.1%) $ 6,804 $ 7,694 (11.6%)
Shareholders' earnings per diluted share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 2.47 $ 1.81 36.5% $ 25.21 $ 25.68 (1.8%)
Add / (Subtract):
Amortization of other intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.74 0.78 2.80 2.49
Net losses on financial instruments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.26 0.32 2.91 1.91
Transaction and integration related costs1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.24 0.29 1.05 0.96
Business dispositions and related items2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.18 0.39 0.18 1.21
Litigation and settlement expenses1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.02 0.05 0.11 2.97
Gain on sale of business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — — — (0.86)
Business optimization charges1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (0.15) — (0.17) 1.15
Tax impact of non-GAAP adjustments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (0.43) (0.40) (1.79) (2.47)
Net adjustment items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.86 1.42 5.08 7.36
Adjusted shareholders' earnings per diluted share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 3.33 $ 3.23 3.1% $ 30.29 $ 33.04 (8.3%)
Three Months Ended
December 31 Twelve Months Ended
December 31
(In millions) 2025 2024 Change 2025 2024 Change
Income before income tax expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 215 $ 606 (64.5%) $ 6,710 $ 7,904 (15.1%)
Net investment income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (493) (527) (2,194) (2,051)
Gain on sale of business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — — — (201)
Net losses on financial instruments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57 74 653 445
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 366 340 1,402 1,185
Amortization of other intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164 180 628 580
Reportable segments operating gain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 309 $ 673 (54.1%) $ 7,199 $ 7,862 (8.4%)
1. Adjustment item resides in the Corporate & Other reportable segment.
2. Adjustment item resides in the Health Benefits, CarelonRx, Carelon Services, and Corporate & Other reportable segments.
13

-- 13 of 17 --

Elevance Health
GAAP Reconciliation
(Unaudited)
Three Months Ended
December 31 Twelve Months Ended
December 31
(In millions) 2025 2024 Change 2025 2024 Change
Reportable segments operating gain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 309 $ 673 (54.1%) $ 7,199 $ 7,862 (8.4%)
Add / (Subtract):
Transaction and integration related costs1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 66 236 224
Business dispositions and related items2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 90 41 281
Litigation and settlement expenses1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 12 24 692
Business optimization charges1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (34) — (38) 268
Net adjustment items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66 168 263 1,465
Reportable segments adjusted operating gain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 375 $ 841 (55.4%) $ 7,462 $ 9,327 (20.0%)
Three Months Ended
December 31 Twelve Months Ended
December 31
(In millions) 2025 2024 Change 2025 2024 Change
Operating expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 5,415 $ 4,804 12.7% $ 20,984 $ 20,025 4.8%
Add / (Subtract):
Transaction and integration related costs1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (54) (66) (236) (224)
Business dispositions and related items2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (41) (90) (41) (281)
Litigation and settlement expenses1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (5) (12) (24) (692)
Business optimization charges1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34 — 38 (268)
Net adjustment items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (66) (168) (263) (1,465)
Adjusted operating expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 5,349 $ 4,636 15.4% $ 20,721 $ 18,560 11.6%
Operating revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 49,311 $ 44,989 9.6% $ 197,584 $ 175,204 12.8%
Operating expense ratio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11.0 % 10.7 % 30 bp 10.6 % 11.4 % (80) bp
Adjusted operating expense ratio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.8 % 10.3 % 50 bp 10.5 % 10.6 % (10) bp
Full Year
2026 Outlook
Shareholders' earnings per diluted share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . At least $22.30
Add / (Subtract):
Amortization of other intangibles3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $2.00
Net losses on financial instruments3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $1.15
Transaction and integration related costs1,3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $0.90
Litigation and settlement expenses1,3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $0.10
Tax impact of non-GAAP adjustments3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Approximately ($0.95)
Net adjustment items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $3.20
Adjusted shareholders' earnings per diluted share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . At least $25.50
1. Adjustment item resides in the Corporate & Other reportable segment.
2. Adjustment item resides in the Health Benefits, CarelonRx, Carelon Services, and Corporate & Other reportable segments.
3. Adjustment item represents the midpoint of a projected range and serves as the estimated full year adjustment amount.
14

-- 14 of 17 --

Elevance Health
Financial Guidance Summary
(Unaudited)
Full Year 2025 Actual Full Year 2026 Outlook
Premium Revenue $164.6 billion Mid single digit decline
Product Revenue $24.5 billion Mid single digit growth
Service Fees $8.5 billion Mid single digit growth
Total Operating Revenue $197.6 billion Low single digit decline
Benefit Expense Ratio 90.0% 90.2% +/- 50 bps
Adjusted Operating Expense Ratio 10.5% 10.6% +/- 50 bps
Adjusted Operating Gain $7.5 billion At least $6.8 billion
Other Pre-Tax Items:
Net Investment income $2,194 million $1,875 million
Interest Expense ($1,402) million ($1,530) million
Amortization of Intangible Assets ($628) million ($440) million
Adjusted Effective Tax Rate 17.6% 22.0% - 24.0%
GAAP Diluted EPS $25.21 At least $22.30
Adjusted Diluted EPS $30.29 At least $25.50
Diluted Shares 224.6 million 219-220 million
Operating Cash Flow $4.3 billion At least $5.5 billion
Segment Level Guidance Metrics
Operating Revenue Growth Rate
Health Benefits $167.1 billion Low single digit decline
CarelonRx $43.4 billion Low single digit growth
Carelon Services $28.3 billion Low single digit growth
GAAP Operating Margin vs. 2025
Health Benefits 2.5% (50) - (25) bps
CarelonRx 5.6% (25) - 0 bps
Carelon Services 3.4% 0 - 25 bps
15

-- 15 of 17 --

Elevance Health
Membership Guidance Summary
(Unaudited)
Full Year 2025 Actual Full Year 2026 Outlook
Year-End Medical Enrollment (in 000s)
Commercial Fee-Based 27,092 27,200 - 27,500
Commercial Risk-Based 4,924 4,150 - 4,250
Medicaid 8,500 7,650 - 7,850
Medicare Advantage 2,230 1,775 - 1,875
Medicare Supplement 882 Approximately 850
Federal Employee Program 1,604 Approximately 1,550
Fee-Based 27,092 27,200 - 27,500
Risk-Based 18,140 15,975 - 16,375
Total 45,232 43,175 - 43,875
16

-- 16 of 17 --

Forward-Looking Statements
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-
looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,”
“feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan,” “potential,” “predict” and similar expressions are
intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their
underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and
statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and
generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-
looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You
are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and
Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent
required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These
risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and
implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other
catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting
healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of cyber-
attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any
investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems; failure of our information
systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data;
changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive
pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties
regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to
maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with
respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with
litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated
with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and
non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; the effects of any negative
publicity or sentiment related to the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures
and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other
intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our
ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and
other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates
or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; events that
may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks
associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers
and business combinations.
17

-- 17 of 17 --